Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Per Karlsson MD, PhD"'
Autor:
Katarina Glise Sandblad MD, Per-Olof Hansson MD, PhD, Jacob Philipson MD, Ahmad Mahmoud MD, Per Karlsson MD, PhD, Annika Rosengren MD, PhD, Jan Sörbo MD, PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 29 (2023)
Cancer is a risk factor for venous thromboembolism (VTE). We aimed to define sex-specific risk of preceding cancer in patients with a first-time VTE by conducting a nationwide Swedish registry-based study including 298 172 patients with VTE and 1 185
Externí odkaz:
https://doaj.org/article/3e91155c5abc4c18aeeabfdaf61a7004
Autor:
Sjöström M; Martin Sjöström, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Anthony Fyles, MD; Fei-Fei Liu, MD; and David McCready, MD, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada; Felix Y. Feng, MD, Department of Radiation Oncology, University of California San Francisco, San Francisco, CA; Corey W. Speers, MD, PhD and Lori J. Pierce, MD, Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; Erik Holmberg, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Mårten Fernö, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Per Malmström, MD, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden; and Per Karlsson, MD, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Fyles A; Martin Sjöström, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Anthony Fyles, MD; Fei-Fei Liu, MD; and David McCready, MD, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada; Felix Y. Feng, MD, Department of Radiation Oncology, University of California San Francisco, San Francisco, CA; Corey W. Speers, MD, PhD and Lori J. Pierce, MD, Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; Erik Holmberg, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Mårten Fernö, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Per Malmström, MD, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden; and Per Karlsson, MD, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Liu FF; Martin Sjöström, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Anthony Fyles, MD; Fei-Fei Liu, MD; and David McCready, MD, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada; Felix Y. Feng, MD, Department of Radiation Oncology, University of California San Francisco, San Francisco, CA; Corey W. Speers, MD, PhD and Lori J. Pierce, MD, Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; Erik Holmberg, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Mårten Fernö, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Per Malmström, MD, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden; and Per Karlsson, MD, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., McCready D; Martin Sjöström, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Anthony Fyles, MD; Fei-Fei Liu, MD; and David McCready, MD, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada; Felix Y. Feng, MD, Department of Radiation Oncology, University of California San Francisco, San Francisco, CA; Corey W. Speers, MD, PhD and Lori J. Pierce, MD, Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; Erik Holmberg, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Mårten Fernö, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Per Malmström, MD, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden; and Per Karlsson, MD, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Feng FY; Martin Sjöström, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Anthony Fyles, MD; Fei-Fei Liu, MD; and David McCready, MD, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada; Felix Y. Feng, MD, Department of Radiation Oncology, University of California San Francisco, San Francisco, CA; Corey W. Speers, MD, PhD and Lori J. Pierce, MD, Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; Erik Holmberg, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Mårten Fernö, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Per Malmström, MD, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden; and Per Karlsson, MD, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Speers CW; Martin Sjöström, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Anthony Fyles, MD; Fei-Fei Liu, MD; and David McCready, MD, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada; Felix Y. Feng, MD, Department of Radiation Oncology, University of California San Francisco, San Francisco, CA; Corey W. Speers, MD, PhD and Lori J. Pierce, MD, Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; Erik Holmberg, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Mårten Fernö, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Per Malmström, MD, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden; and Per Karlsson, MD, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Pierce LJ; Martin Sjöström, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Anthony Fyles, MD; Fei-Fei Liu, MD; and David McCready, MD, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada; Felix Y. Feng, MD, Department of Radiation Oncology, University of California San Francisco, San Francisco, CA; Corey W. Speers, MD, PhD and Lori J. Pierce, MD, Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; Erik Holmberg, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Mårten Fernö, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Per Malmström, MD, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden; and Per Karlsson, MD, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Holmberg E; Martin Sjöström, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Anthony Fyles, MD; Fei-Fei Liu, MD; and David McCready, MD, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada; Felix Y. Feng, MD, Department of Radiation Oncology, University of California San Francisco, San Francisco, CA; Corey W. Speers, MD, PhD and Lori J. Pierce, MD, Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; Erik Holmberg, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Mårten Fernö, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Per Malmström, MD, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden; and Per Karlsson, MD, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Fernö M; Martin Sjöström, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Anthony Fyles, MD; Fei-Fei Liu, MD; and David McCready, MD, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada; Felix Y. Feng, MD, Department of Radiation Oncology, University of California San Francisco, San Francisco, CA; Corey W. Speers, MD, PhD and Lori J. Pierce, MD, Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; Erik Holmberg, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Mårten Fernö, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Per Malmström, MD, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden; and Per Karlsson, MD, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Malmström P; Martin Sjöström, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Anthony Fyles, MD; Fei-Fei Liu, MD; and David McCready, MD, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada; Felix Y. Feng, MD, Department of Radiation Oncology, University of California San Francisco, San Francisco, CA; Corey W. Speers, MD, PhD and Lori J. Pierce, MD, Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; Erik Holmberg, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Mårten Fernö, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Per Malmström, MD, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden; and Per Karlsson, MD, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Karlsson P; Martin Sjöström, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Anthony Fyles, MD; Fei-Fei Liu, MD; and David McCready, MD, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada; Felix Y. Feng, MD, Department of Radiation Oncology, University of California San Francisco, San Francisco, CA; Corey W. Speers, MD, PhD and Lori J. Pierce, MD, Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; Erik Holmberg, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Mårten Fernö, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Per Malmström, MD, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden; and Per Karlsson, MD, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Aug 10; Vol. 41 (23), pp. 3959-3960. Date of Electronic Publication: 2023 Jun 06.